Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
Rajni Kant, Gaurav Raj Dwivedi, Kamran Zaman, Rima R. Sahay, Gajanan Sapkal, Himanshu Kaushal, Dimpal A. Nyayanit, Pragya D. Yadav, Gururaj Deshpande, Rajeev Singh, Sandeep Chaowdhary, Nivedita Gupta, Sanjay Kumar, Priya Abraham, Samiran Panda, Balram Bhargava
Abstract
The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
Topics & Concepts
HeterologousImmunogenicityMedicineVaccinationVirologyImmunologyImmunizationAdverse effectRegimenAntibodyInternal medicineBiologyGeneBiochemistrySARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisVaccine Coverage and Hesitancy